Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

MAS063DP

National Institutes of Health

Related topics

Related topics

5 relations

Narrower (2)

ATOPICLAIRZarzenda

Broader (3)

Dietary FatsGlycyrrhetinic acidPlant Extracts

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Efficacy of MAS063DP lotion vs 0.02% triamcinolone acetonide lotion in improving post‐ablative fractional CO2 laser resurfacing wound healing: a split‐face, triple‐blinded, randomized, controlled…
Proven as effective acne scar treatment, ablative fractional carbon dioxide (AFCO2) laser requires post‐laser wound healing care… Expand
Review
2016
Review
2016
Impact of Measuring Patient-Reported Outcomes in Dermatology Drug Development
Although some symptoms of dermatologic diseases, such as pruritus and pain, can be subjectively assessed only by patients, the… Expand
2010
2010
MAS063DP is Effective Monotherapy for Mild to Moderate Atopic Dermatitis in Infants and Children: A Multicenter, Randomized, Vehicle-Controlled Study
2009
2009
MAS063DP Is Effective Monotherapy for Mild to Moderate Atopic Dermatitis in Infants and Children: A Multicenter, Randomized, Vehicle-Controlled Study
Boguniewicz M, Zeichner JA, Eichenfield LF, et al. J Pediatr . 2008;152(6):854–859 PURPOSE OF THE STUDY. To examine the safety… Expand
2009
2009
MAS063DP jest skuteczny monoterapii łagodnych i umiarkowanych postaci atopowego zapalenia skóry (AZS) u niemowląt i dzieci: Wieloośrodkowa, randomizowana, próba z placebo
Streszczenie Przedmiot Analiza skuteczności i bezpieczenstwa kremu MAS063DP (Atopiclair) w leczeniu lagodnych i umiarkowanych… Expand
2008
2008
A double‐blind, randomized, vehicle‐controlled clinical study to evaluate the efficacy and safety of MAS063DP (ATOPICLAIRTM) in the management of atopic dermatitis in paediatric patients
A multicenter, randomized, double‐blind, vehicle‐controlled clinical study was conducted to evaluate the efficacy and safety of… Expand
2008
2008
MAS063DP is effective monotherapy for mild to moderate atopic dermatitis in infants and children: a multicenter, randomized, vehicle-controlled study.
OBJECTIVE To examine the efficacy and safety of MAS063DP (Atopiclair) cream in the management of mild to moderate atopic… Expand
  • figure 1
2008
2008
Patient‐reported outcomes from a multicenter, randomized, vehicle‐controlled clinical study of MAS063DP (Atopiclair™) in the management of mild‐to‐moderate atopic dermatitis in adults
Background: MAS063DP (Atopiclair™) is a topical cream approved for symptomatic relief in the treatment of atopic and contact… Expand
Highly Cited
2006
Highly Cited
2006
A multicenter, randomized, vehicle-controlled clinical study to examine the efficacy and safety of MAS063DP (Atopiclair) in the management of mild to moderate atopic dermatitis in adults.
BACKGROUND MAS063DP cream has received marketing authorization in the US and the European Union for symptom relief of atopic… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE